Investment Rating - The investment rating for the company is "Buy-A" with a target price of 41.6 yuan over the next six months [3][4]. Core Insights - The company has entered into a strategic partnership with Quanterix to enhance its Alzheimer's disease (AD) detection capabilities, leveraging Quanterix's Simoa technology for early diagnosis and treatment monitoring [1]. - The market for AD detection is expected to grow significantly, with projections indicating that by 2030, there will be approximately 19.11 million AD patients aged 60 and above in China, creating a substantial demand for early screening and diagnosis [2]. - The company anticipates strong revenue growth, with projected increases of 30.0%, 18.1%, and 30.8% for the years 2024 to 2026, respectively, alongside net profit growth rates of 41.2%, 15.2%, and 31.4% during the same period [3][11]. Financial Summary - The company's revenue for 2024 is estimated at 621 million yuan, increasing to 734 million yuan in 2025 and 960 million yuan in 2026 [11]. - The net profit is projected to reach 246 million yuan in 2024, 283 million yuan in 2025, and 372 million yuan in 2026 [11]. - The earnings per share (EPS) is expected to grow from 1.81 yuan in 2024 to 2.08 yuan in 2025 and 2.73 yuan in 2026 [13].

1 / 3 的突破。 证券代码：688253 证券简称：英诺特 公告编号：2025-007 北京英诺特生物技术股份有限公司关于公司及子公 司近期获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司及子公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）全资子公司英诺特 （唐山）生物技术有限公司（以下简称"唐山英诺特"）近期新取得产品资质 4 项，具体情况如下表所示： | 序 | 获批主 | 产品名称 | 注册证号（备案号） | 发证日期 | 有效期至 | | --- | --- | --- | --- | --- | --- | | 号 | 体 | | | | | | | （1）泰国产品文号 | 项 2 甲型流感病毒、乙型流感病毒、合 | | | | | | 唐山英 | 胞病毒、偏肺病毒、腺病毒、副流 | | | | | 1 | | 感病毒、新型冠状病毒抗原联合 | 68-2-2-1-0001620 | 2025/2/14 | 2029/12/31 | | | 诺特 ...

Core Viewpoint - The article emphasizes the importance of HBM (High Bandwidth Memory) in the AI chip sector and highlights the need for domestic production capabilities in China to overcome reliance on foreign technology and equipment [1][2]. Group 1: HBM Technology and Market Landscape - HBM has become a "performance multiplier" in AI chips, data centers, and supercomputing due to its 3D stacking architecture and ultra-high bandwidth performance [1]. - The global HBM market is dominated by SK Hynix, Samsung, and Micron, with China's HBM industry facing a domestic equipment localization rate of less than 5%, which is a significant barrier to the development of local storage chips [2]. Group 2: Challenges in HBM Manufacturing - Key technical barriers in HBM manufacturing include precision limits, complex processes, quality requirements for DRAM, yield and cost challenges, and the need for scalable mass production [1]. - The precision required for chip stacking is at the sub-micron or even tens of nanometers level, which is critical to avoid interconnection failures or signal degradation [1]. Group 3: Domestic Innovations and Solutions - Beijing Huazhuo Precision Technology Co., Ltd. (Huazhuo Precision) has developed a series of high-end equipment aimed at HBM chip manufacturing, including hybrid bonding equipment and laser annealing devices, to address the "bottleneck" in domestic HBM chip production [1][2]. - Huazhuo Precision's equipment matrix aims to provide a complete set of key process solutions, enabling Chinese HBM companies to "overtake on a bend" in the face of ongoing U.S. semiconductor equipment restrictions [2][3]. Group 4: Strategic Importance - The push for HBM localization has reached a national information security strategy level, highlighting the critical nature of developing domestic capabilities in semiconductor technology [2]. - Huazhuo Precision's innovations not only fill the gap in key equipment localization but also aim to transition China's storage industry from "import substitution" to "defining standards," leading to continuous technological iterations [3].

证券代码：688253 证券简称：英诺特 公告编号：2025-006 北京英诺特生物技术股份有限公司 三、 其他事项 | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 211.2740 万股 | | 累计已回购股数占总股本比例 | 1.5483% | | 累计已回购金额 | 7,801.24 万元 | | 实际回购价格区间 | 28.62 元/股~45.37 元/股 | 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机拟用于 员工持股计划或股权激励。公司本次回购价格不超过人民币 50.00 元/股（含），回 购股 ...

Financial Performance - The company achieved total operating revenue of 621.34 million yuan, a year-on-year increase of 29.98%[2] - Net profit attributable to the parent company reached 245.69 million yuan, reflecting a year-on-year growth of 41.24%[5] - The net profit excluding non-recurring gains and losses grew by 47.52% year-on-year, reaching 216.93 million yuan[9] - Basic earnings per share increased by 41.41% to 1.81 yuan[2] - The increase in operating profit by 37.12% and total profit by 38.50% is attributed to favorable market conditions in the respiratory testing sector[9] Assets and Returns - The company's total assets at the end of the reporting period were 2.22 billion yuan, an increase of 7.33% from the beginning of the period[5] - The weighted average return on net assets rose to 12.67%, an increase of 2.8 percentage points compared to the previous year[2] Strategic Initiatives - The company plans to enhance its core competitive advantages by increasing investments in channel network construction and international market access[7] - The company is focusing on digital and intelligent upgrades to improve operational efficiency and risk control capabilities[7] Cautionary Note - The company warns that the financial data presented are preliminary and subject to final audit, urging investors to be cautious[10]

证券代码：688253 证券简称：英诺特 公告编号：2025-004 北京英诺特生物技术股份有限公司 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机拟用于 员工持股计划/或股权激励。公司本次回购价格不超过人民币 50.00 元/股（含），回 购股份金额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含），回 购股份的实施期限自董事会审议通过本次回购方案之日起 12 个月内。具体内容详 见公司于 2024 年 8 月 3 日在上海证券交易所网站（www.sse.com.cn）披露的《关 于以集中竞价方式回购公司股份方案的公告》（公告编号：2024-030）及 2024 年 8 月 8 日披露的《关于以集中竞价方式回购股份的回购报告书》（公告编号：2024-035）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定， ...

| 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 158.7406 万股 | | 累计已回购股数占总股本比例 | 1.1633% | | 累计已回购金额 | 万元 6,201.26 | | 实际回购价格区间 | 元/股~45.37 元/股 28.62 | 证券代码：688253 证券简称：英诺特 公告编号：2025-003 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股 本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定 ...

Financial Projections - The company expects to achieve an annual operating revenue of approximately RMB 621.34 million for 2024, representing a year-on-year growth of about 29.98%[3] - The projected net profit attributable to shareholders for 2024 is approximately RMB 245.70 million, reflecting a year-on-year increase of about 41.25%[3] - In 2023, the company reported an operating revenue of RMB 478.02 million and a net profit of RMB 173.95 million[5] Market Development - The growth in performance is attributed to the ongoing development of the national hierarchical medical system and increased awareness of early diagnosis and treatment among patients[6] - The company is actively expanding its market presence in both tiered hospitals and grassroots medical markets[6] Financial Data Disclaimer - The financial data provided in the forecast has not been audited by a registered accountant[4] - Investors are advised that the forecast data is preliminary and the final figures will be disclosed in the official 2024 annual report[8] - The company emphasizes the importance of recognizing investment risks associated with the preliminary financial data[8]

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-014 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | 投资者关系活 动类别 | £ □ | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating that the stock is expected to outperform the benchmark index by more than 20% over the next 12 months [5][15]. Core Insights - The company's revenue for the first three quarters of 2024 reached approximately 521 million yuan, representing a year-on-year growth of 87.05%. The net profit attributable to the parent company was about 245 million yuan, up 182.65% year-on-year [2][3]. - The rapid growth of the non-COVID respiratory product series is highlighted, with revenue from this segment accounting for approximately 84.83% in 2023 and increasing to 97.74% in the first half of 2024. This segment includes various testing kits for respiratory pathogens [2][3]. - The company has been expanding its overseas market presence, recently obtaining product approvals in Malaysia and Myanmar, which is expected to accelerate revenue growth from international markets [2][3]. Summary by Sections Financial Performance - For the first three quarters of 2024, the gross margin, net profit margin, and net profit margin after deducting non-recurring items were 81.0%, 47.0%, and 43.0%, respectively, showing increases of 9.35, 15.88, and 19.27 percentage points year-on-year [2]. - The company forecasts revenues of 782 million yuan, 943 million yuan, and 1.119 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 356 million yuan, 463 million yuan, and 567 million yuan [3][4]. Market Outlook - The respiratory pathogen testing market is in a rapid growth phase, and the company is positioned as a leading player in this sector, expected to benefit from industry expansion [3]. - The report anticipates that the company's overseas business will become a new growth engine as more product qualifications are approved [2][3].